1. The use of alispovir for the treatment of a patient infected with hepatitis C virus of genotype 1 in combination with standard treatment, characterized in that: (i) the patient is a patient with a relapse or a patient who does not respond to treatment, and (ii) alispovir is administered during the initial phase in an amount of about 600 mg twice a day； followed by the introduction of alispovir during the second phase in an amount of from about 600 to about 1000 mg once a day. 2. The use according to claim 1, characterized in that alispovir is administered during the initial phase in an amount of about 600 mg twice a day for 7 days； followed by the introduction of alispovir during the second phase in an amount of about 600 or about 1000 mg or 800 mg once a day for a period of up to 23, 47 or 71 weeks. 3. The use according to claim 2, characterized in that alispovir is administered during the initial phase in an amount of about 600 mg twice a day for 7 days； followed by the introduction of alispovir during the second phase in an amount of 600 mg once a day for a period of up to 47 weeks. 4. The use of claim 1, wherein the standard treatment is a combination of interferon with ribavirin. The use according to claim 4, wherein said interferon is pegylated interferon alpha-2a, and is administered in an amount of 180 micrograms once a week. The use of claim 4, wherein said ribavirin is administered in the range between 1000 mg and 1200 mg per day. A method of treating a hepatitis C virus infected with genotype 1 patient with a relapse of the disease or a patient who does not respond to treatment with alispovir in combination with standard treatment, including the administration of alispovir during the initial phase in an amount of about 600 m�1. Применение алисповира для лечения пациента, инфицированного вирусом гепатита C генотипа 1 в комбинации со стандартным лечением, отличающийся тем, что:(i) пациент является пациентом с рецидивом заболевания или пациентом, не отвеч
